The striking preclinical profile of StroMAb .…predicts both a significant improvement in efficacy and major reductions in risk….could revolutionize the treatment of ischemic stroke.
(PRWEB) November 21, 2013
Translational Sciences Inc. announces that StromAb is in production on Phase I Clinical Trials. Production began after completing highly successful pre-clinical development studies showing exceptional efficacy and safety in multiple disease models.
StromAb is a first-in-class antibody providing immediate safe dissolution of ACUTE blood clots that cause > 2 million cases of ischemic stroke, venous thrombosis, pulmonary embolism, heart attack and acute peripheral vascular ischemia in the U.S. alone.
Translational Sciences Inc. holds exclusive licensing rights with Massachusetts General Hospital & Harvard University.
Distinct from existing agents or agents in development: StromAb occupies a different therapeutic space, than anticoagulants (e.g., heparins, or direct thrombin or factor Xa inhibitors etc.). StromAb rapidly dissolves clots in ACUTE cardiovascular diseases; anticoagulants inhibit blood clot formation but do not dissolve clots.
However, StromAb is also compatible with anticoagulants in the therapeutic process.
StromAb was selected by NIH for therapeutic development grants. StromAb is supported by multiple patents and patent actions.
Translational Sciences is currently exploring partnerships for future clinical trials.
Experts Have Commented:
- “The striking preclinical profile of StroMAb .…predicts both a significant improvement in efficacy and major reductions in risk….could revolutionize the treatment of ischemic stroke.”
- “This is a highly significant project that addresses the most important unmet medical need for safe drugs to treat acute thrombotic diseases with poor prognosis (stroke, heart attack, pulmonary embolism, arterial thrombosis)."
- “These antibodies have the potential to dramatically change the course of treatment of thromboembolic stroke and other ischemic diseases.”
Translational Sciences, Inc. is a privately held biopharmaceutical company that translates scientific insights into first-in-class, biologic agents for cardiovascular diseases.
Interested parties may contact Translational Sciences at 901-274-4506 or email David Pedersen, dpedersen(at)translationalsciences(dot)com